Are the loading dose treatment groups superior to the 150 mg without loading dose group in the secukinumab FUTURE 5 study?
- PMID: 29853450
- DOI: 10.1136/annrheumdis-2018-213770
Are the loading dose treatment groups superior to the 150 mg without loading dose group in the secukinumab FUTURE 5 study?
Keywords: disease activity; psoriatic arthritis; treatment.
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.Ann Rheum Dis. 2018 Jun;77(6):890-897. doi: 10.1136/annrheumdis-2017-212687. Epub 2018 Mar 17. Ann Rheum Dis. 2018. PMID: 29550766 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
